Work

Thoracoscopic lobectomy following neoadjuvant tyrosine kinase inhibitor treatment

Year: 2021

Type: article

Abstract: Tyrosine kinase inhibitor (TKI) therapy is approved for the treatment of stage IV non–small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation. Comparison of TKI versus conventional platinum doublet-based chemotherapy in stage IV NSCLC has demonstrated improved progression-free survival with TKI therapy.1,2 The recently published phase III FLAURA trial found superior overall survival with osimertinib, a third-generation TKI, compared with the second-generation TKIs gefitinib or erlotinib, in patients with previously untreated EGFR mutation-positive advanced NSCLC.

Source: JTCVS Techniques

DOI: 10.1016/j.xjtc.2021.02.005

Authors: Neel P. Chudgar, David R. Jones

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,100